...Okay. So let's get started. On behalf of Vivoryon, I warmly welcome you all to today's breakfast and networking event around the AAIC 2022. Thanks for joining us this morning. It's great to have so many of you here in the room with us in San Diego and I know that there are many of you who are joining virtually, so a warm welcome to you as well. For those of you who don't know me, my name is Ulrich Dauer, I'm Vivoryon's CEO. Together with my team, I'm thrilled to have this opportunity to discuss the future of Alzheimer's disease treatments with you and renowned experts in the field who will provide an overview of our carefully crafted clinical development strategy and updates on our active Phase 2 VIVA-MIND and VIVIAD studies for varoglutamstat, as well as our exciting therapeutic target and our preclinical antibody PBD-C06. Now between May 2016 and May '21, so within 5 years, the FDA approved 207 cancer drugs. In Alzheimer's disease, the last 19 years have only seen a single approval. And...